A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

Relapsed/Refractory B-cell Lymphoma Introduction

PI3K Signaling Pathway

α and δ PI3K Isoforms

Targeted PI3K Inhibitor Therapy

Practical Differences

Clinical Trial Data

Idelalisib

Phase 2 Trial of Idelalisib Monotherapy in RR FL

Phase 2 Idelalisib Monotherapy AEs of Interest

CHRONOS-1 Copanlisib Methods

CHRONOS-1 Copanlisib Results

Common AEs Associated With Idelalisib and Copanlisib

TGR-1202 (Umbralisib)

Safety of Umbralisib

ASH 2017 Data

Phase 3 DUOTM Trial Duvelisib vs Ofatumumab

Phase 3 DUOTM Trial Safety & Conclusions

Safety Analysis of Umbralisib in R/R Lymphoid Malignancies

Safety Analysis of Umbralisib in R/R Lymphoid Malignancies - Results

Updated Safety and Efficacy From Copanlisib CHRONOS-1 Trial: Efficacy

Updated Safety and Efficacy From Copanlisib CHRONOS-1 Trial: Safety

Pooled Safety Analysis From Phase 1 and 2 Studies for Relapsed iNHL Treated With IV Copanlisib

Pooled Safety Analysis for Relapsed iNHL Treated With IV Copanlisib, cont.

Applying the Data

Future Directions

Closing Remarks

Abbreviations